Biomea Fusion To Host Conference Call And Webcast On Wednesday, October 30 At 4:30 Pm ET To Announce Lead Clinical Candidate, BMF-650, A Oral Small-Molecule GLP-1 Receptor Agonist And Preclinical Data Combining BMF-219 With A GLP-1 RA-Based Therapy
Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday
Biomea Fusion Analyst Ratings
Biomea Fusion Initiated With a Buy at EF Hutton
Biomea Fusion To Present Data From The Company's COVALENT-111 and COVALENT-112 Diabetes Clinical Trials Will Be Featured During A Long Oral Presentation And Two Short Oral Presentations At The 1st Asian Conference On Innovative Therapies For Diabetes...
Independent Director of Biomea Fusion Michael J. Hitchcock Buys 200% More Shares
Biomea Fusion Forms Global Scientific Advisory Board
Express News | Biomea Announces Formation of Global Scientific Advisory Board With 22 World-Renowned Diabetes Experts
IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Deliver On Growth Plans?
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $10
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $41
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $10 to $60
Biomea Fusion Price Target Raised to $41.00/Share From $21.00 by Scotiabank
Biomea Upgraded by Analysts After FDA Lifts Clinical Hold
Express News | HC Wainwright & Co. Maintains Buy on Biomea Fusion, Raises Price Target to $40
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
Biomea Fusion's FDA Hold Seen as Possible Blessing in Disguise -- Market Talk
Biomea Fusion Is Maintained at Equal-Weight by Barclays
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $9 to $60